Investigating onset of Chemobrain in Chemotherapy patients: A pilot study comparing early versus late onset of cognitive impairment (CHEMOBRAIN)

Study ID
STU 012016-091

Study Sites

  • Clements University Hospital

Sonja Stutzman

Principal Investigator
Kelly Moore


This is a prospective, non-randomized, pilot feasibility,observational study of adult chemotherapy patients. eligible patients will be consented and assessed for their cognitive function. The study will compare the cognitive function of patients who are newly initiating chemotherapy to those that have had at least two doses of chemotherapy. Data will be collected from the assessments, as well as data abstraction of demographic information from the electronic medical record. eligible patients will participate in the study for approximately two months.

Participant Eligibility

Participants will be considered eligible if they meet the following criteria:

* Over the age of 18

* Cancer Diagnosis (as determined in the EMR)

* Orders for Chemotherapy to be received at Simmons Comprehensive Cancer Center, Forth Worth and Dallas locations

* Cognitively able to self-consent

* English Speaking

* Life expectancy greater than 3 months